Genomic-Enabled Medicine for Recurrent Glioblastoma

In this prospective study, we performed genome-wide tumor/normal exome sequencing and tumor RNA-sequencing for recurrent glioblastoma patients. A subset of patients had both enhancing tumor and non-enhancing tissue sequenced to investigate spatial heterogeneity of this disease. Together, this information builds our understanding of the genomic underpinnings of glioblastoma, and contributes toward the knowledge base for identifying and developing more effective treatments for patients with glioblastoma.]]>
For genome profiling To be eligible for this part of the study, the following inclusion and exclusion criteria must be adhered to: Inclusion Criteria for Molecular Profiling Patients must understand and provide written informed consent and HIPAA authorization prior to initiation of any study-specific procedures Have a life expectancy ≥ 3 months Patients must have a diagnosis of histologically confirmed Glioblastoma that is felt on imaging to be progressive despite standard of care treatment ≥ 18 years of age Patient is a good medical candidate for a standard of care surgical procedure Patients may enroll independent of number of prior therapies, but must have received prior radiation therapy Patients must have a performance status (KPS) of ≥ 60 Exclusion Criteria Uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent ]]>
Version 1 included the data from the prospective clinical trial. Version 2 was updated to include longitudinal data and additional data from non-enhancing tissue regions.]]>